Synapse - Genitourinary Oncology Service

Results (5692)

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Ben, Tran; Horvath, L.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Autio, K. A.; Rottey, S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914)

Meeting Abstract

Bex, A.; Russo, P.; Tomita, Y.; Grunwald, V.; Ramirez, L. M.; McHenry, B. M.; Motzer, R. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

HCRN GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC)

Meeting Abstract

Balar, A. V.; Funt, S. A.; Gupta, S.; Dudek, A. Z.; Boiles, A. R.; Vaena, D. A.; Kilari, D.; Rosenberg, J. E.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity

Meeting Abstract

Zhang, Z.; Zhou, C.; Li, X.; Barnes, S.; Deng, S.; Hoover, E.; Chen, C. C.; Lee, Y. S.; Wang, C.; Tirado, C.; more...
Cancer Research (2020)

Fulltext@MSK | Save

OncoKB, a precision oncology knowledgebase

Meeting Abstract

Suehnholz, S.; Zhang, H.; Nissan, M.; Kundra, R.; Su, J.; LaFave, L.; Gala, K.; Vanderbilt, C.; Arcila, M.; Ladanyi, M.; more...
Cancer Research (2020)

Fulltext@MSK | Save

IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)